Direct Genomics is providing physicians with the first single molecule sequencer built exclusively for the clinic.
Direct Genomics is making genomics an affordable part of everyday patient care. The company’s GenoCare instrument is the first single molecule sequencing system for clinical use. That simplifies sequencing by directly reading individual DNA and RNA molecule information from customer’s blood or tissue samples, delivering significant improvements in cost and speed. Established in 2012, Direct Genomics is headquartered in Shenzhen, China and backed by institutional and private investors.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 19, 2018 | Series A | $34.80M | 1 | Cosun Venture Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Cosun Venture Capital | Yes | Series A |